Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 10, 2008, Pages 1163-1171

  Pérez Simón, José A ^a   Encinas, Cristina ^a   Silva, Fernando ^a   Arcos, Maria José ^a   Díez Campelo, María ^a   Sánchez Guijo, Fermín M ^a   Colado, Enrique ^a   Martín, Jesús ^a   Vazquez, Lourdes ^a   del Cañizo, Consuelo ^a   Caballero, Dolores ^a   San Miguel, Jesús ^a  

^a CSIC   (Spain)

Author keywords

Chronic graft versus host disease; peripheral blood stem cell transplantation; scoring system

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; FOLINIC ACID; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE SEVERITY; DONOR; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; REDUCED INTENSITY CONDITIONING; SCORING SYSTEM; SURVIVAL RATE;

AGE DISTRIBUTION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LUNG DISEASES; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 51649093276     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.07.015     Document Type: Article

References (20)

1. Socié G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341 (1999) 14-21
2. Duell T., Van Lint M.T., Ljungman P., et al. Health and functional status of long-term survivors of bone marrow transplantation: EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Bone Marrow Transplantation. Ann Intern Med 126 (1997) 184-192
3. Pérez Simón J.A., Sánchez-Abarca I., Díez-Campelo M., et al. Chronic graft-versus-host disease: pathophysiology and clinical management. Drugs 66 (2006) 1041-1057
4. Wingard J.R., Piantadosi S., Vogelsang G.B., et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74 (1989) 1428-1435
5. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic-graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
6. Atkinson K., Horowitz M.M., Gale R.P., et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 4 (1989) 247-254
7. Akpek G., Zahurac M., Piantadosi S., et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97 (2001) 1219-1226
8. Lee S.J., Klein J.P., Barret A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100 (2002) 406-414
9. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft versus host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005) 945-956
10. Lee S.J. New approaches for preventing and treating chronic graft-versus-host disease. Blood 105 (2005) 4200-4206
11. Randolph S.S., Gooley T.A., Warren E.H., et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 103 (2004) 347-352
12. Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Stem Cell Trialists' Collaborative Group. J Clin Oncol 23 (2005) 5074-5087
13. Flowers M.E., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100 (2002) 415-419
14. Pavletic S., Smith L., Bishop M., et al. Prognostic factors of chronic graft-versus-host disease after blood stem cell transplantation. Am J Hematol 78 (2005) 265-274
15. + cell dose on the outcome of patients undergoing reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Blood 102 (2003) 1108-1113
16. Stewart B.I., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104 (2004) 3501-3506
17. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26 (2008) 577-584
18. Pérez Simón J.A., Caballero D., Mateos M.V., et al. Graft-vs-host disease and graft-vs-myeloma effect after non-myeloablative allogeneic transplantation. Leuk Lymphoma 45 (2004) 1725-1729
19. Martino R., Caballero D., Pérez-Simón J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
20. Lee S.J., Vogelsang G., and Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9 (2003) 215-233